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Alzheimer’s disease (AD) is characterized by a progressive loss of memory and cognitive
decline. However, the assessment of AD-associated functional and cognitive changes
is still a big challenge. Auditory-evoked cortical potential (AECP) is an event-related
potential reflecting not only neural activation in the auditory cortex (AC) but also cognitive
activity in the brain. In this study, we used the subdermal needle electrodes with
the same electrode setting as the auditory brainstem response (ABR) recording and
recorded AECP in normal aging CBA/CaJ mice and APP/PS1 AD mice. AECP in mice
usually appeared as three positive peaks, i.e., P1, P2, and P3, and three corresponding
negative peaks, i.e., N1, N2, and N3. In normal aging CBA mice, the early sensory peaks
P1, N1, and P2 were reduced as age increased, whereas the later cognitive peaks N2,
P3, and N3 were increased or had no changes with aging. Moreover, the latency of
the P1 peak was increased as age increased, although the latencies of later peaks had
a significant reduction with aging. In AD mice, peak P1 was significantly reduced in
comparison with wild-type (WT) littermates at young ages, proceeding AD phenotype
presentation. In particular, the later cognitive peak P3 was diminished after 3 months
old, different from the normal aging effect. However, the latencies of AECP peaks in
AD mice generally had no significant delay or changes with aging. Finally, consistent
with AECP changes, the accumulation of amyloid precursor protein (APP) at the AC
was visible in AD mice as early as 2 months old. These data suggest that AECP could
serve as an early, non-invasive, and objective biomarker for detecting AD and AD-related
dementia (ADRD).
Keywords: auditory-evoked cortical potential, auditory cortex, Alzheimer’s disease, dementia, hearing loss,
cognitive decline, mouse model, event-related potential

INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by a progressive
loss of memory and dementia. Over the last two decades, the prevalence of AD and AD-related
dementia (ADRD) has been rapidly increased. It is prospected that there will be 150 million AD
patients by the year 2050, almost triple the population in 2018 (Hebert et al., 2013; Patterson, 2018).
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AD-induced functional changes in the AC and brain with aging.
We found that AECP in AD mice had a significant reduction at
young ages. In particular, later cognitive peak P3 in AD mice
was diminished, different from the normal aging effect. Our
study suggests that AECP recording could serve as an early
non-invasive biomarker to assess AD and ADRD development.

This will produce a heavy economic and social burden. Early
detection is critical for the prevention and interventions of this
common neurodegenerative disease. It is estimated that early
diagnosis and interventions delaying the onset of dementia by
even 1 year could decrease the worldwide prevalence of dementia
by 10% (Patterson, 2018). However, since the lack of early, reliable
AD biomarkers, early detection of AD is still a big challenge.
In particular, it lacks objective biomarkers to detect cognitive
decline, which is the most common and predominant symptom
of AD, at the early stage.
Recently, increasing evidence suggests that defects in sensory
systems, including the olfactory, visual, and auditory systems,
are highly associated with AD progression (Murphy, 2019;
Rochoy et al., 2019). AD pathology could appear in sensoryassociated areas before appearing in regions involving memory,
such as the entorhinal and hippocampal areas (Gates et al., 2002;
Murphy, 2019). These neuropathological changes in the sensoryassociated areas could also occur before cognitive symptoms
become apparent. Hearing is an important neural sense. AD can
cause hearing loss, and hearing loss can in turn accelerate AD
and dementia development (Morrison et al., 2018; Griffiths et al.,
2020). Our previous study demonstrated that auditory brainstem
response (ABR), which reflects the function and integrity of the
auditory pathway in the brainstem, had a reduction in APP/PS1
AD mice at the age of 3 months old (Liu et al., 2020), prior to
the occurrence of typical AD phenotypes, such as spatial learning
deficit, in this AD mouse model by the age of 6–7 months
old (Reiserer et al., 2007; Ordóñez-Gutiérrez et al., 2015, 2016).
Recent studies also found that deficits in auditory gap detection
could occur in young 5xFAD mice (Kaylegian et al., 2019; Weible
et al., 2020). These studies suggest that AD could cause hearing
function decline at the early stage and that hearing function tests
could provide important information for AD development at
the early stage.
Auditory-evoked cortex potential (AECP) is an event-related
potential evoked by auditory stimulation and reflects the neural
activity in the auditory cortex (AC) and the related brain areas.
In humans, AECP consists of several waveforms and are named
as P1 (P50), N1 (N100), P2 (P200), N2 (N250), P3 (P300), and
P4 (P600) based on their latencies (Swords et al., 2018). Early
waveforms (i.e., P1 and P2) are “sensory,” largely depending on
the stimulus and activities in the AC; later waveforms (i.e., P3 and
P4) are “cognitive” reflecting cognitive processing (Sur and Sinha,
2009). Thus, unlike ABR, the AECP can reflect not only the neural
activities in the AC but also the cognitive activities in the brain.
In previous studies, auditory-evoked potentials were recorded
in the cortex, hippocampus, and other brain areas with implanted
electrodes in AD animal models (Wang et al., 2003; Stoiljkovic
et al., 2019) or amyloid-β (Aβ) injected in the rat and mouse
brain at different ages (Hidisoglu and Yargicoglu, 2020; Kim
et al., 2020). In general, auditory-evoked potentials in the AC
and other brain cortexes were reduced in AD or amyloidinjected animals. However, there were conflicting results in the
literature (Gurevicius et al., 2013). AD-induced auditory-evoked
potential changes in the brain and their dynamic changes in AD
development still remain largely undetermined. In this study, we
systematically recorded AECP in APP/PS1 AD mice to assess
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MATERIALS AND METHODS
APP/PS1 AD Mice and CBA/CaJ Normal
Aging Mice
APP/PS1 transgenic mice were purchased from Jackson
Laboratory, United States (Stock No: 004462, mixed C57BL/6;
C3H genetic background). Since the C57BL/6 genetic
background is associated with age-related hearing loss, we
crossed APP/PS1 mice with CBA/CaJ mouse strain (Stock No:
00654, Jackson Laboratory, Bar Harbor, ME, United States),
which has no apparent age-related hearing loss (Zheng et al.,
1999), for four generations. APP/PS1 transgenic mice possess
both chimeric mouse/human amyloid precursor protein (APP)
(Mo/HuAPP695swe) and mutant human presenilin 1 (PS1-dE9)
(Reiserer et al., 2007). According to the technical notice of
Jackson Laboratory, APP/PS1 transgenes were detected by PCR
amplification of tail genomic DNA using the following primers:
wild-type (WT) forward: 50 -GTG TGA TCC ATT CCA TCA
GC-30 ; common: 50 -GGA TCT CTG AGG GGT CCA GT-30 ;
mutant forward: 50 -ATG GTA GAG TAA GCG AGA ACA
CG-30 . Mutant and WT mice generated 142 and 265 bps bands,
respectively. WT littermates served as controls. Both genders
were used in the experiment. CBA/CAJ mice were also used
for the normal aging studies. All experiments and procedures
were approved and conducted in accordance with the policies
of the University of Kentucky Animal Care and Use Committee
(approved protocol: UK#2020-3524).

Auditory-Evoked Cortical Potential
Recording
Auditory-evoked cortical potential was recorded in a double-wall
sound isolated chamber by use of a Tucker-Davis R3 system with
an ES-1 high-frequency speaker (Tucker-Davis Tech., Alachua,
FL, United States). Mice were anesthetized by intraperitoneal
injection with a mixture of ketamine and xylazine (8.5 ml
saline + 1 ml ketamine + 0.55 ml xylazine, 0.1 ml/10 g). Body
temperature was maintained at 37–38◦ C by placing anesthetized
mice on an isothermal pad. As the same as ABR recording (Liu
et al., 2020), two subdermal needle electrodes were punched into
the head skin at the vertex and ventrolaterally to the right or
left ear. The ground needle electrode was inserted into the right
leg. Cortical potentials were evoked by clicks (85 dB SPL) in
alternative polarity with a stimulating rate of 1/s. The recording
time window was 800 ms, starting from the beginning of the
stimulation. The signal was amplified by 50,000 and averaged by
200 times. The recording filter was set at 0–3 kHz. The signal
recording was performed by BioSigRP software (Tucker-Davis
Tech.). The collected signals were further filtered in offline with
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P2, and P3, and three corresponding negative peaks, i.e., N1,
N2, and N3 (Figure 1). Like AECP recorded from humans,
both early sensory peaks (P1, N1, and P2) and later cognitive
waves (P3 and N3) were visible in the recording. However, the
later cognitive wave P3 in mice was not clearly visible until
the age of 3 months old (Figures 1A,B). At 6 months old,
AECP in mice was well developed, and P1, P2, and P3 peaks
were clearly visible (Figure 1C). The latencies of peaks P1, P2,
and P3 were 13.5 ± 1.89, 67.5 ± 2.74, and 128.1 ± 6.76 ms,
respectively (Figure 2A).

a build-in 10-order digital Gaussian filter with 12.5 Hz of central
frequency and a bandwidth of 2 octaves for analysis.

Brain Slide Preparation and
Immunofluorescent Staining
Mice were anesthetized with ketamine as described above
and intracardially perfused with 4% paraformaldehyde for 15–
20 min. After decapitation, the mouse skull was opened. The
brain was carefully removed and incubated overnight in 4%
paraformaldehyde for postfixation. Following infiltration with
30% glucose for 3 days with changing fresh solution at each day,
the brain was embedded in OCT (Cat # 4583, Sakura Finetek
USA, Inc., Torrance, CA, United States) at room temperature for
1 day. Then, the embedded brain was frozen at −80◦ C overnight
and cut 20 µm thick at −22–24◦ C by a cryostat (Thermo Electron
Corp., Waltham, MA, United States). The tissue sections were
directly mounted onto glass slides for staining and storage.
Immunofluorescent staining was performed as described
in our previous reports (Zhao and Yu, 2006; Wang et al.,
2009). After 1 h of incubation with the blocking solution
(10% goat serum and 1% BSA in PBS) with 0.5% Triton X100 at room temperature, the brain slides were incubated with
primary antibody rabbit monoclonal anti-APP (clone Y188)
(#AB32136, Abcam, Waltham, MA, United States; 1:500) in
blocking solution at 4◦ C overnight. After washout with PBS three
times, the brain slides were incubated at room temperature with
corresponding secondary antibody conjugated with Alexa Fluor568 (Thermo Fisher Scientific, MA, United States) for 2 h. At the
last 15 min, 40 ,6-diamidino-2-phenylindole (DAPI, 0.1 mg/ml,
D1306; Molecular Probes) was added into the incubation solution
to visualize the cell nuclei. After completely washing out the
secondary antibodies with PBS, the sections were mounted
with a fluorescence mounting medium H-1000, Vector Lab,
CA, United States) and observed under a Nikon A1R confocal
microscope system. The AD and WT mouse sections were
simultaneously stained and observed with the same parameters.

Normal Aging Changes of AECP in
CBA/CaJ Mice
We further investigated the effect of normal aging on AECP.
CBA/CAJ mice, which have no apparent age-related hearing
loss (Zheng et al., 1999), were used. Figure 1 shows that
AECPs in CBA mice were reduced with increased age. The
amplitudes of early peaks (i.e., P1, N1, and P2) were 4.66 ± 0.70,
−4.73 ± 0.71, and 3.15 ± 0.75 µV, respectively, at 12 months old
and 3.39 ± 0.77, −3.98 ± 0.78, and 3.41 ± 0.86 µV, respectively,
at 18 months old (Figures 2C,D). In comparison with those at the
age of 3 months, the amplitudes of P1, N1, and P2 at 12 months
old had a significant reduction (p = 0.003−0.022, t-test, twotailed). However, the peak P3 was significantly increased from
2.03 ± 0.31 µV at 3 months old to 3.47 ± 0.56 µV at 12 months
old (p = 0.037, t-test, two-tailed) (Figure 2C). The amplitudes
of later peaks N2 and N3 had no significant changes with
aging (Figure 2D).
The latency of P1 peak had a significant increase at 6 and
12 months (p = 0.014 and 0.045, respectively, t-test, two-tailed)
(Figure 2B). However, there was no significant change in the N1
latency with aging; the latencies of peaks P2, N2, P3, and N3 were
significantly reduced (p = 0.004−0.045, t-test, two-tailed) at 6 and
12 months old but had no significant changes at 18 months old in
comparison with them at 3 months old (Figure 2B).

AECP in APP/PS1 AD Mice
Data Processing, Statistical Analysis,
and Reproducibility

Figure 3 shows AECP traces recorded from APP/PS1 AD mice
and WT littermates at different ages. In general, P1 and P2 in
AECP in AD mice appeared smaller than those in WT littermate
mice at young ages. At the age of 1–3 months old, there was a
notch at the descending side of peak P2 in AD mice (indicated by
blue arrows in Figures 3A–C). P3 is clearly visible in WT mice
after 4 months old (indicated by red arrows in Figures 3D–I),
but small or invisible in AD mice (Figures 3D–I). Later negative
peaks of N2 and N3 were also small or invisible in AD mice
(Figures 3D–I).

The amplitude and latency of peaks in AECP were measured by
a house-made program with MATLAB (MathWorks Inc., MA,
United States). Data were plotted by SigmaPlot and statistically
analyzed by SPSS v25.0 (SPSS Inc., Chicago, IL, United States).
Data were expressed as mean ± SEM. Student’s t-tests were
performed between APP and WT groups at the defined age.
When three or more groups were compared, one-way ANOVA
with Bonferroni post hoc test was used. The threshold for
significance was α = 0.05. The AECP was recorded from mice
generated by more than 15 different breeding pairs.

Changes of AECP in APP/PS1 AD Mice
With Aging
To quantify changes of AECP in AD mice, we measured peaks
of AECP at different ages (Figure 4). Quantitative measurement
shows that the early P1 peak in AD mice at 3–7 months old
was significantly reduced in comparison with those in WT mice
(p = 0.014−0.046, t-test, two-tailed) (Figure 4A). The amplitudes
of later cognitive P3 peak in AD mice were also significantly

RESULTS
AECP in Mice
Figure 1 shows AECP recorded from mice. The AECP recorded
from mice usually appeared as three positive peaks, i.e., P1,
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FIGURE 1 | Auditory-evoked cortex potential (AECP) in CBA/CaJ mice at different ages. AECP was evoked by a click stimulus (85 dB SPL) in alternative polarity.
Traces were averaged from the recorded mice with both genders. Error bars represent SEM. Mouse age is indicated in each panel. N is the mouse number. AECP in
mice has three positive peaks, i.e., P1, P2, and P3, and three corresponding negative N1, N2, and N3 peaks. Red arrows indicate P3 peak that is clearly visible in
AECP at 3 months old and afterward.

that in WT mice (p = 0.049, t-test, two-tailed) at 12 months
old (Figure 5D).

smaller than WT mice after 3 months old (p = 0.049−0.005,
t-test, two-tailed) (Figure 4E). However, the peak N1 and P2
in AD mice had no significant changes except 4 months old, at
which they had a significant reduction in comparison with WT
mice (p = 0.046−0.048, t-test, two-tailed) (Figures 4B,C). Later
peaks N2 and N3 in AD mice also had no significant reduction in
comparison with WT mice except 10–12 months old, at which the
N3 peak in AD mice was significantly reduced (p = 0.024−0.047,
t-test, two-tailed) (Figure 4F).
The latencies of AECP peaks in AD mice usually had no
significant changes or appeared shortening except a few time
points (Figure 5). For example, there was no significant difference
in latencies of positive peaks (P1, P2, and P3) between AD and
WT mice except 3 months old (Figure 5A), at which the latency
of P1 peak in AD mice was significantly shorter than that in
WT mice (p = 0.0007, t-test, two-tailed). For negative peaks,
the latency of peak N1 in AD mice appeared shorter than that
in WT mice (p = 0.0003−0.02, t-test, two-tailed) at 1, 3, and
6 months old (Figure 5B). The latency of N3 peak in AD mice
also appeared shorter than those in WT mice (p = 0.012−0.049,
t-test, two-tailed) at 10–12 months old (Figure 5F). However,
the latency of peak N2 in AD mice appeared longer than

Frontiers in Aging Neuroscience | www.frontiersin.org

Different Changes of AECP in AD Mice
and CBA/CaJ Mice With Aging
We further examined AECP changes in AD mice, WT littermate
mice, and CBA mice at different ages (Figure 6). Changes of
AECP in WT littermates and CBA mice with normal aging were
similar. However, P1 peak in AD mice had a significant reduction
at 3 and 6 months old (p = 0.024−0.035, one-way ANOVA with
a Bonferroni correction) (Figure 6A). Also, P3 peak in AD mice
at 3–12 months old was significantly reduced in comparison with
that in WT littermates and CBA mice (p = 0.0005−0.036, oneway ANOVA with a Bonferroni correction) (Figure 6E). The later
peaks of N2 and N3 in AD mice were also significantly reduced
at 12 months old (p = 0.004−0.024, one-way ANOVA with a
Bonferroni correction) (Figures 6D,F). However, there were no
significant differences in N1 and P2 peaks among AD mice, WT
littermates, and CBA mice (Figures 6B,C).
To assess the aging effect on AECP in AD mice, WT
littermates, and CBA mice, the amplitudes of AEACP peaks at
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FIGURE 2 | Changes of AECP in normal aging CBA/CaJ mice. N is the mouse number. (A) P1, P2, and P3 peak times at the age of 6 months old. The green line in
the box represents the mean level. (B) Changes of AECP peak times in normal aging. The statistical t-tests were performed by comparing peak times at the defined
age to that at 3 months old in each peak. (C,D) Changes of peak amplitudes with aging. The amplitudes of early peaks P1, N1, and P2 in AECP are decreased with
aging, whereas the peak amplitudes of later waveforms N2, P3, and N3 are increased or have no significant change with aging. The statistical analyses were
performed by comparing peak amplitudes at the defined age to that at age of 3 months old in each peak. *p < 0.05, **p < 0.01, t-test, two-tailed.

antibody (clone Y188, aa750 to the C-terminus) (#AB32136,
Abcam, United States) for immunofluorescent staining. This
antibody can also react with gamma secretase fragments and
C-terminal fragments. Immunofluorescent staining shows that
positive labeling was visible at the AC in APP/PS1 AD mice at
2 months old (Figures 8B,E), consistent with early changes in
the AECP recording. However, there was no labeling visible in
WT control mice at the same age (Figure 8C). As age increased,
the deposition of labeling in the AC was increased. At the age of
1 year old, the typical accumulating pattern of plaque deposition
was clearly visible in the AC (Figures 8A,D).

different ages were normalized to those at 3 months old in each
group. Figure 7 shows that the early sensory P1, N1, and P2 peaks
in CBA mice and WT littermates were decreased as age increased
and had a significant reduction at the age of 12 months old in
comparison with those at 3 months old (p = 0.0003−0.02, t-test,
two-tailed). However, the peak P1, N1, and P2 in AD mice had
no significant reduction or change with aging (Figures 7A–C).
For later cognitive peaks, N2, P3, and N3 in CBA mice and
WT littermates appeared to increase with aging (Figures 7D–F).
In comparison with 3 months old, the increases of N2 in WT
littermates at 12 months, P3 peak in CAB mice at 12 months,
and N3 peak in WT littermates at 6 months old were significant
(p = 0.023−0.037, t-test, two-tailed). However, AECP in AD mice
had no significant changes as age increased, except N3 peak at
12 months was significantly decreased in comparison with that at
6 months old (p = 0.006, t-test, two-tailed) (Figure 7F).

DISCUSSION
In this study, we used the same subdermal needle electrodes and
setting as the ABR recording and recorded AECP in mice and
characterized changes of AECP in APP/PS1 AD mice and normal
aging CBA/CaJ mice. Like the AECP recorded from humans,
both early sensory and later cognitive waves were visible in the
recorded mouse AECP, which usually presented three waveforms
(Figure 1). The later cognitive peak P3 was not clearly visible until
3 months old (Figure 1B). As age increased, the early peaks (P1,

Expression of APP at the Auditory Cortex
in APP/PS1 AD Mice
Since APP/PS1 transgenic mice possess both chimeric
mouse/human APP (Mo/HuAPP695swe) and mutant human
presenilin 1 (PS1-dE9) (Reiserer et al., 2007), we used anti-APP
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FIGURE 3 | AECP traces were recorded from APP/PS1 AD mice at different ages. WT littermates served as control. Red and black traces represent averaged AECP
traces recorded from APP/PS1 AD mice and WT mice, respectively. Error bars represent SEM. Mouse age is indicated in each penal. N is the mouse number. Blue
arrows indicate a notch at the descending side of peak P2 in AD mice at 1–3 months old. Red arrows indicate the P3 peak clearly visible in WT mice but not in AD
mice after 3 months old.

we used subdermal needle electrodes with the same electrode
configuration (or setting) as ABR recording and recorded
AECP from ketamine-anesthetized mice. The recorded AECP
waveforms are like AECP recorded from humans (Golob et al.,
2009; Swords et al., 2018); both early sensory and later cognitive
peaks were visible in the recording (Figures 1, 3). However, in
comparison with the AECP recorded from humans, the AECP
in mice appeared only as three waveforms (Figure 1). Also, the
latencies of P1, P2, and P3 in mice were in the range of 10–15, 65–
70, and 110–150 ms, respectively (Figures 2A,B), and appeared
much shorter than humans (Golob et al., 2009; Swords et al.,
2018). This may be due to the mouse brain size is small and
the neural interactions are less than humans. In addition, P3 in
mice was not well developed until 3 months old (Figure 1). As
mentioned above, later waveforms in AECP are associated with
cognitive processing (Sur and Sinha, 2009). Specifically, P3 is
dependent on internal thought process and is considered to be
mainly generated by the hippocampus where short-term memory
is stored. These data suggest that such cognition-associated
neural activity in mice may need to take a longer time for
maturation in the development. These data are also consistent

N1, and P2) in AECP were reduced, while later peaks (i.e., N2,
P3, and N3) were increased or had no changes (Figures 1, 2, 7).
In APP/PS1 AD mice, P1 peak at young ages (<8 months old)
appeared smaller than those in WT mice (Figures 3, 4, 6). In
particular, the later cognitive peak P3 in AD mice was diminished
(Figures 3, 4, 6). As age increased, there were no significant
changes in AECP in AD mice except peak N3 at 1 year old
(Figure 7). Also, there was no significant peak delay in AD mice
except peak N2 at 1 year old (Figure 5). Finally, consistent with
early changes of AECP in young ages, intensive labeling for APP
was visible in the AC of AD mice at 2 months old (Figure 8).
These data suggest that AECP could serve as an early, noninvasive biomarker to detect and assess AD development and
progression.
In previous studies, various auditory-evoked potentials were
recorded from animals with implanted electrodes in the brain
(Wang et al., 2003; Gurevicius et al., 2013; Kim et al., 2020).
However, different from AECP recorded from humans, only
early sensory peaks P1 and P2 were visible in those animal
recordings; later cognitive peaks were usually missing or invisible
even in the recording in the waking animals. In this study,
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FIGURE 4 | Changes of AECP peaks in APP/PS1 AD mice with aging. WT littermates served as control. Peaks of AECP recorded from each mouse were measured
and averaged. Peak name is presented at the top middle place in each panel. N is the mouse number. The amplitudes of peak P3 in AD mice are significantly less
than those in WT mice after 3 months old. *p < 0.05, **p < 0.01, t-test, two-tailed.

FIGURE 5 | Changes of AECP peak times in APP/PS1 AD mice with aging. Peak name is presented at the top middle place in each panel. N is the mouse number.
The peak times in AD mice were compared with those in WT littermates at the same age. *p < 0.05, **p < 0.01, t-test, two-tailed.
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FIGURE 6 | Comparison of AECP changes in CBA/CaJ mice, APP/PS1 AD mice, and WT littermate mice. Peak name is presented at the top middle place in each
panel. Animal numbers in each group are presented within the bars in panel (A). Panel (E) shows that peak P3 in the AD mice has a significant reduction in
comparison with those in CBA and WT littermate mice. *p < 0.05, **p < 0.01, one-way ANOVA with a Bonferroni correction.

FIGURE 7 | Effects of aging on AECP in CBA/CaJ, APP/PS1 AD, and WT littermate mice. The amplitudes of peaks were normalized to those at 3 months old in
each group. Peak name is presented at the top middle place in each panel. N is the animal number. The statistical t-test with two-tailed was performed by
comparing data at 3 months or data at 6 months within each group. Early AECP peaks (P1, N1, and P2) in CBA mice and WT littermates are decreased as age
increased, while later peaks (N2, P3, and N3) are increased or not changed with aging. However, AD mice have no significant changes in AECP peaks with aging
except peak N3 at 12 months old, which is decreased. *p < 0.05, **p < 0.01, t-test, two-tailed, vs. 3 months; ## p < 0.01, t-test, two-tailed, vs. 6 months.
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FIGURE 8 | Expression of amyloid precursor protein (APP) in the auditory cortex (AC) in APP/PS1 AD mice. (A–C) Immunofluorescent staining of brain slices in
APP/PS1 AD mice and WT mice at the ages of 2 and 12 months old. (D,E) High-magnitude images of positive labeling in the AC area. The positive labeling is visible
at the AC area in the APP/PS1 AD mouse at 2 months old. White arrows indicate plaque deposits in the AC area at the 12 months old mouse. Scale bar: 100 µm in
(A–C), 10 µm in (D,E).

In this study, consistent with AECP recording, we found that
the accumulation of APP in the AC could be visible in AD mice as
early as 2 months old (Figure 8). As age increased, extracellular
Aβ-like plaque deposits were also visible (Figure 8D). Previous
studies demonstrated that the human brain stem and AC in old
AD patients had AD pathology including Aβ plaques, tau protein
aggregation, and neural degeneration (Ohm and Braak, 1989;
Sinha et al., 1993; Baloyannis et al., 2007, 2009). Our results
are consistent with these previous reports and provide further
morphological evidence that AD could occur in the auditory
system at the early stage.
In comparison with WT littermates, AECP in AD mice
usually appeared small (Figures 3, 4, 6). This is consistent with
previous reports that AD patients had changes in auditoryevoked potentials (Buchwald et al., 1989; Irimajiri et al., 2005;
Swords et al., 2018). In particular, the later cognitive peak P3
in AD mice was diminished (Figures 3, 4, 6), different from
the normal aging effect (Figure 7). This is also consistent
with a previous report that different from the normal aging
effect, cognitive N200 and P300 peaks (i.e., N2 and P3 peaks
in mice) in AD patients were reduced (Morrison et al.,
2018). We further found that as age increased, the early
peaks (P1, N1, and P2) in normal aging CBA mice and WT
littermates were decreased but the later peaks (N2, P3, and N3)
were increased or not changed (Figures 2, 7), although the

with previous reports that memory-based detection and neural
activities are recordable in the anesthetized mice (Chen et al.,
2015; Kurkela et al., 2018).
The sensory P1 peak in AD mice appeared smaller than WT
mice at young ages (<8 months old) (Figures 3, 4, 6). These
data are consistent with previous reports that AD or amyloid
injection could reduce evoked potentials in the AC and other
brain cortexes in animal models (Wang et al., 2003; Stoiljkovic
et al., 2019; Hidisoglu and Yargicoglu, 2020; Kim et al., 2020).
These data also indicated that AD could result in functional
changes in the AC at the early AD stage. It has been reported that
APP/PS1 AD mice usually appear typical AD phenotypes, such
as spatial learning deficit, by the age of 6–7 months old (Reiserer
et al., 2007; Ordóñez-Gutiérrez et al., 2015, 2016). We previously
reported that hearing loss measured as ABR threshold occurred
in APP/PS1 AD mice as early as 2–3 months old; ABR wave IV–
V were reduced or diminished (Liu et al., 2020). 5xFAD mice also
had early onset of deficits in auditory gap detection at 2 months
old (Kaylegian et al., 2019; Weible et al., 2020). These data suggest
that AECP recording, as well as ABR recording and other hearing
function tests, could provide important information for early
AD development and progression. These data also support the
concept that auditory sensory and cognitive cortical potentials
in AD persons could be abnormal before AD becomes apparent
(Golob et al., 2009).
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CBA mice have no significant hearing loss as measured by ABR
at least until 1 year old (Zheng et al., 1999). Thus, these data
implicate that AECP is dependent not only on brainstem input, in
particular, but also on the later peaks in AECP, which are mainly
generated by the hippocampus-associated short-term memory
(Sur and Sinha, 2009).
The AECP in AD mice had a significant reduction in
comparison with WT littermates (Figures 3, 4, 6). However,
the AECP in AD mice had no significant changes with aging
(Figure 7). This may be due to AECP in AD mice is already
reduced and cannot be further reduced as aging increased.
In addition, there was no significant delay of AECP peaks in
AD mice (Figure 5), although the latencies of peaks of AECP
in normal aging CBA mice were reduced with increased age
(Figure 2B). Actually, the latencies of peak P1 and N1 in AD
mice at 1–3 months old (Figures 5B–D) and the latencies of
N3 at 10–12 months old (Figure 5F) were shorter than those
in WT mice. This may arise from the fact that the neural
interactions in AD mice may be less than WT mice due to neural
degeneration in AD mice.
At present, more and more AD mouse models are available
and they provide useful animal models to study AD pathological
mechanisms, develop therapeutic interventions, and assess the
treatment efficiency. However, due to the lack of reliable
objective biomarkers, it is still a big challenge to assess cognitive
decline in animals, in particular, at the early AD stage. In this
study, we found that later cognitive peak P3 of AECP in AD
mice was diminished, different from the normal aging effect
(Figures 3, 4, 6, 7). These data suggest that AECP could serve
as an objective recording to assess cognitive decline in mice. This
will greatly facilitate AD animal studies.
In this study, we reported a new method by using subdermal
needle electrodes with the same electrode configuration as
ABR recording to record AECP in anesthetized mice. The

recorded AECP was similar to AECP recorded from humans,
had both early sensory and later cognitive peaks, and showed
distinct response patterns in AD mice from normal aging
effect (Figures 1–3, 6, 7). These data suggest that hearing
functional tests, including AECP recording, could serve as
simple, non-invasive, repeatable biomarkers to assess AD, and
ADRD development and progression.
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